Tuberous Sclerosis – Epidemiology – Mature Markets
DRG Epidemiology’s coverage of tuberous sclerosis comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United States, France, Germany, Italy, Spain, the United Kingdom, and Japan). We report the prevalence of tuberous sclerosis for each country, as well as annualized case counts projected to the national population.
Most patient populations are forecast over a period of 20 years for the major mature pharmaceutical markets covered in this report.
DRG Epidemiology’s tuberous sclerosis forecast will answer the following questions:
- How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of tuberous sclerosis over the forecast period?
All forecast data are available on the DRG Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.
In total, DRG Epidemiology forecasts six tuberous sclerosis patient populations, as follows:
- Diagnosed prevalent cases.
- Diagnosed prevalent cases with the TSC1 genotype.
- Diagnosed prevalent cases with the TSC2 genotype.
- Diagnosed prevalent cases with no mutation identified.
- Diagnosed prevalent cases with epilepsy.
- Diagnosed prevalent cases with developmental delays.
- … and more (details available on request).
Note: Coverage may vary by country.
Table of contents
- Tuberous Sclerosis - Epidemiology - Mature Markets
- Introduction
- Key Findings
- Key Updates
- Overview
- Prevalence of Tuberous Sclerosis per 100,000 People of All Ages in 2021 and 2041ttttttttt
- Relative Sizes of the Factors Contributing to the Trend in Prevalent Cases of Tuberous Sclerosis over the Next 20 Yearsttttttttt
- Analysis of the Prevalent Cases of Tuberous Sclerosis in 2021 by Genotypettttttttt
- Key Findings
- Epidemiology Data
- Methods
- Diagnosed Prevalent Cases
- Diagnosed Prevalent Cases by Genotype
- Diagnosed Prevalent Cases by Comorbidity
- Reference Material
- Literature Review
- Studies Included in the Analysis of Tuberous Sclerosis
- Studies Excluded from the Analysis of Tuberous Sclerosis
- Risk/protective factors
- Risk/Protective Factors
- Risk/Protective Factors
- Bibliography
- Abbreviations
- Glossary
- Literature Review
- Introduction
Jai Oberoi, M.P.H., is an associate epidemiologist at Clarivate. Previously, he was a research specialist at Emory University, where he analyzed whole genome/exome data. He obtained his M.P.H. in epidemiology and applied biostatistics from Columbia University, where he conducted research on the phenotypic and genotypic markers of aging.
Oliver Blandy, M.Sc., is a senior epidemiologist at Clarivate. Previously, Oliver worked as a research assistant for Imperial College London, where he was the lead for several studies within an NIRH-funded research group investigating healthcare-associated infections and antimicrobial resistance. He holds an M.Sc. from the University of Bristol, where he specialized in nutrition, physical activity, and public health. He also holds a B.Sc. in chemistry and a postgraduate certificate in education, both from the University of Bristol.